GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OPKO Health Inc (NAS:OPK) » Definitions » ROE %

OPKO Health (OPKO Health) ROE %

: -18.77% (As of Dec. 2023)
View and export this data going back to 1995. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. OPKO Health's annualized net income for the quarter that ended in Dec. 2023 was $-265.9 Mil. OPKO Health's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $1,416.9 Mil. Therefore, OPKO Health's annualized ROE % for the quarter that ended in Dec. 2023 was -18.77%.

The historical rank and industry rank for OPKO Health's ROE % or its related term are showing as below:

OPK' s ROE % Range Over the Past 10 Years
Min: -20.23   Med: -10.61   Max: 1.86
Current: -12.62

During the past 13 years, OPKO Health's highest ROE % was 1.86%. The lowest was -20.23%. And the median was -10.61%.

OPK's ROE % is ranked worse than
57.34% of 218 companies
in the Medical Diagnostics & Research industry
Industry Median: -6.24 vs OPK: -12.62

OPKO Health ROE % Historical Data

The historical data trend for OPKO Health's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OPKO Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.49 1.86 -1.80 -20.23 -12.80

OPKO Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.37 -4.69 -5.09 -22.68 -18.77

Competitive Comparison

For the Diagnostics & Research subindustry, OPKO Health's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OPKO Health ROE % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, OPKO Health's ROE % distribution charts can be found below:

* The bar in red indicates where OPKO Health's ROE % falls into.



OPKO Health ROE % Calculation

OPKO Health's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-188.863/( (1561.648+1389.219)/ 2 )
=-188.863/1475.4335
=-12.80 %

OPKO Health's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-265.932/( (1444.568+1389.219)/ 2 )
=-265.932/1416.8935
=-18.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


OPKO Health  (NAS:OPK) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-265.932/1416.8935
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-265.932 / 727.616)*(727.616 / 2034.189)*(2034.189 / 1416.8935)
=Net Margin %*Asset Turnover*Equity Multiplier
=-36.55 %*0.3577*1.4357
=ROA %*Equity Multiplier
=-13.07 %*1.4357
=-18.77 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-265.932/1416.8935
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-265.932 / -289.976) * (-289.976 / -276.236) * (-276.236 / 727.616) * (727.616 / 2034.189) * (2034.189 / 1416.8935)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9171 * 1.0497 * -37.96 % * 0.3577 * 1.4357
=-18.77 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


OPKO Health ROE % Related Terms

Thank you for viewing the detailed overview of OPKO Health's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


OPKO Health (OPKO Health) Business Description

Traded in Other Exchanges
Address
4400 Biscayne Boulevard, Miami, FL, USA, 33137
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a global supply-chain operation and holding company in Ireland. Opko also owns a speciality active pharmaceutical ingredients manufacturer in Israel. The company's bio-reference testing business consists of routine testing and esoteric testing. Routine tests measure various health parameters, such as the functions of the heart, kidney, liver, thyroid, and other organs.
Executives
Frost Phillip Md Et Al 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Hsiao Jane Ph D director 4400 BISCAYNE BLVD, MIAMI FL 33137
Gary J. Nabel director, officer: Chief Innovation Officer C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Elias A. Zerhouni director, officer: Vice Chairman and President 2099 PENNSYLVANIA AVENUE, NW 12TH FLOOR, WASHINGTON DC 20006
John A Paganelli director, other: Chairman of the Board OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Pfenniger Richard C Jr director 4400 BISCAYNE BLVD., MIAMI FL 33137
Alexis Borisy director C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 16TH FLOOR, CAMBRIDGE MA 02142
Jon R Cohen director, officer: SVP OPKO; Exec Chairman BRLI C/O OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Prem A Lachman director 4400 BISCAYNE BLVD., MIAMI FL 33137
Roger Md Medel director 1301 CONCORD TERRACE, SUNRISE FL 33323
Rulfo Fernando Hernandez officer: CAO, Treasurer C/O OPKO HEALTH INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Anthony J Japour director 19805 N. CREEK PARKWAY, BOTHELL WA 98011
Robert Scott Fishel director C/O OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Adam Logal officer: Exec.Dir .of Fin., CAO,Treas. OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137